Evaluating blood biomarkers to aid diagnosis and treatment in drug-naïve patients with depression
EVALUATION PROSPECTIVE DE L'AIDE AU DIAGNOSTIC ET AU TRAITEMENT PAR BIOMARQUEURS SANGUINS CHEZ DES PATIENTS DRUG-NAÏFS AMBULATOIRES SOUFFRANT DE DEPRESSION
This study is testing if blood samples can help doctors better diagnose and treat people with depression or bipolar disorder who are just starting medication.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Les Toises - Psychiatry and Psychotherapy Center Academic / other |
| Locations | 1 site (Lausanne) |
| Trial ID | NCT06369792 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on drug-naïve outpatients diagnosed with depression or bipolar disorders who are beginning treatment with specific medications. Participants will have five blood samples collected at various intervals after starting their treatment to assess the relationship between blood biomarkers and treatment response. The primary goal is to enhance early diagnosis and optimize pharmacological treatment, ultimately guiding personalized clinical practices. This study does not influence the choice or dosage of the medication prescribed.
Who should consider this trial
Good fit: Ideal candidates are adult drug-naïve outpatients suffering from depression or bipolar disorders who are starting treatment with escitalopram, fluoxetine, sertraline, or quetiapine.
Not a fit: Patients with a history of harmful use of psychoactive substances or those lacking the capacity for discernment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and individualized treatment plans for patients with depression and bipolar disorders.
How similar studies have performed: While this approach is innovative, similar studies exploring blood biomarkers in mental health have shown promise, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult drug-naïve outpatients suffering from depression and/or bipolar disorders who start a pharmacological treatment with escitalopram, fluoxetine, sertraline or quetiapine and who gave his written informed consent to participate in the present study. Exclusion Criteria: * Any patient without capacity of discernment or with harmful use of psychoactive substances
Where this trial is running
Lausanne
- Les Toises - Psychiatry and Psychotherapy Center — Lausanne, Switzerland (Recruiting)
Study contacts
- Study coordinator: Aurélie Reymond-Delacrétaz, PhD
- Email: aurelie.delacretaz@lestoises.ch
- Phone: 0041 584-580-580
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.